Cargando…

Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study

Patients with end-stage kidney disease (ESKD) are at increased risk for SARS-CoV-2 infection and its complications compared with the general population. Several studies evaluated the effectiveness of COVID-19 vaccines in the dialysis population but showed mixed results. The aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkadi, Mohamad M., Hamad, Abdullah, Ghazouani, Hafedh, Elshirbeny, Mostafa, Ali, Mohamed Y., Ghonimi, Tarek, Ibrahim, Rania, Abuhelaiqa, Essa, Abou-Samra, Abdul Badi, Al-Malki, Hassan, Butt, Adeel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863461/
https://www.ncbi.nlm.nih.gov/pubmed/36679894
http://dx.doi.org/10.3390/vaccines11010049
_version_ 1784875340146933760
author Alkadi, Mohamad M.
Hamad, Abdullah
Ghazouani, Hafedh
Elshirbeny, Mostafa
Ali, Mohamed Y.
Ghonimi, Tarek
Ibrahim, Rania
Abuhelaiqa, Essa
Abou-Samra, Abdul Badi
Al-Malki, Hassan
Butt, Adeel A.
author_facet Alkadi, Mohamad M.
Hamad, Abdullah
Ghazouani, Hafedh
Elshirbeny, Mostafa
Ali, Mohamed Y.
Ghonimi, Tarek
Ibrahim, Rania
Abuhelaiqa, Essa
Abou-Samra, Abdul Badi
Al-Malki, Hassan
Butt, Adeel A.
author_sort Alkadi, Mohamad M.
collection PubMed
description Patients with end-stage kidney disease (ESKD) are at increased risk for SARS-CoV-2 infection and its complications compared with the general population. Several studies evaluated the effectiveness of COVID-19 vaccines in the dialysis population but showed mixed results. The aim of this study was to determine the effectiveness of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection in hemodialysis (HD) patients in the State of Qatar. We included all adult ESKD patients on chronic HD who had at least one SARS-CoV-2 PCR test done after the introduction of the COVID-19 mRNA vaccines on 24 December 2020. Vaccinated patients who were only tested before receiving any dose of their COVID-19 vaccine or within 14 days after receiving the first vaccine dose were excluded from the study. We used a test-negative case–control design to determine the effectiveness of the COVID-19 vaccination. Sixty-eight patients had positive SARS-CoV-2 PCR tests (cases), while 714 patients had negative tests (controls). Ninety-one percent of patients received the COVID-19 mRNA vaccine. Compared with the controls, the cases were more likely to be older (62 ± 14 vs. 57 ± 15, p = 0.02), on dialysis for more than one year (84% vs. 72%, p = 0.03), unvaccinated (46% vs. 5%, p < 0.0001), and symptomatic (54% vs. 21%, p < 0.0001). The effectiveness of receiving two doses of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection was 94.7% (95% CI: 89.9–97.2) in our HD population. The findings of this study support the importance of using the COVID-19 mRNA vaccine in chronic HD patients to prevent SARS-CoV-2 infection in such a high-risk population.
format Online
Article
Text
id pubmed-9863461
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98634612023-01-22 Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study Alkadi, Mohamad M. Hamad, Abdullah Ghazouani, Hafedh Elshirbeny, Mostafa Ali, Mohamed Y. Ghonimi, Tarek Ibrahim, Rania Abuhelaiqa, Essa Abou-Samra, Abdul Badi Al-Malki, Hassan Butt, Adeel A. Vaccines (Basel) Communication Patients with end-stage kidney disease (ESKD) are at increased risk for SARS-CoV-2 infection and its complications compared with the general population. Several studies evaluated the effectiveness of COVID-19 vaccines in the dialysis population but showed mixed results. The aim of this study was to determine the effectiveness of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection in hemodialysis (HD) patients in the State of Qatar. We included all adult ESKD patients on chronic HD who had at least one SARS-CoV-2 PCR test done after the introduction of the COVID-19 mRNA vaccines on 24 December 2020. Vaccinated patients who were only tested before receiving any dose of their COVID-19 vaccine or within 14 days after receiving the first vaccine dose were excluded from the study. We used a test-negative case–control design to determine the effectiveness of the COVID-19 vaccination. Sixty-eight patients had positive SARS-CoV-2 PCR tests (cases), while 714 patients had negative tests (controls). Ninety-one percent of patients received the COVID-19 mRNA vaccine. Compared with the controls, the cases were more likely to be older (62 ± 14 vs. 57 ± 15, p = 0.02), on dialysis for more than one year (84% vs. 72%, p = 0.03), unvaccinated (46% vs. 5%, p < 0.0001), and symptomatic (54% vs. 21%, p < 0.0001). The effectiveness of receiving two doses of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection was 94.7% (95% CI: 89.9–97.2) in our HD population. The findings of this study support the importance of using the COVID-19 mRNA vaccine in chronic HD patients to prevent SARS-CoV-2 infection in such a high-risk population. MDPI 2022-12-26 /pmc/articles/PMC9863461/ /pubmed/36679894 http://dx.doi.org/10.3390/vaccines11010049 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Alkadi, Mohamad M.
Hamad, Abdullah
Ghazouani, Hafedh
Elshirbeny, Mostafa
Ali, Mohamed Y.
Ghonimi, Tarek
Ibrahim, Rania
Abuhelaiqa, Essa
Abou-Samra, Abdul Badi
Al-Malki, Hassan
Butt, Adeel A.
Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study
title Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study
title_full Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study
title_fullStr Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study
title_full_unstemmed Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study
title_short Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study
title_sort effectiveness of messenger rna vaccines against sars-cov-2 infection in hemodialysis patients: a case–control study
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863461/
https://www.ncbi.nlm.nih.gov/pubmed/36679894
http://dx.doi.org/10.3390/vaccines11010049
work_keys_str_mv AT alkadimohamadm effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT hamadabdullah effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT ghazouanihafedh effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT elshirbenymostafa effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT alimohamedy effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT ghonimitarek effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT ibrahimrania effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT abuhelaiqaessa effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT abousamraabdulbadi effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT almalkihassan effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy
AT buttadeela effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy